Last reviewed · How we verify
Insulin Aspart 30
Insulin Aspart 30 is a rapid-acting insulin analog that binds to insulin receptors on cells to facilitate glucose uptake and lower blood glucose levels.
Insulin Aspart 30 is a rapid-acting insulin analog that binds to insulin receptors on cells to facilitate glucose uptake and utilization for energy and storage. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Aspart 30 |
|---|---|
| Also known as | Novomix 30 |
| Sponsor | Medical University of Graz |
| Drug class | Insulin analog (rapid-acting/intermediate-acting combination) |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin Aspart is a recombinant human insulin analog with a rapid onset of action, designed to mimic the body's natural insulin response to meals. The '30' designation indicates this is a premixed formulation containing 30% insulin aspart and 70% insulin aspart protamine suspension, providing both rapid and intermediate glucose control. It works by binding to insulin receptors on muscle, fat, and liver cells, promoting glucose uptake and storage while suppressing hepatic glucose production.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (PHASE2)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- The Impact of Two Different Insulin Dose Calculation on Postprandial Glycemia After Mixed Meal. (PHASE4)
- iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (PHASE3)
- HbA1c Variability in Type II Diabetes (NA)
- Total-body Glucose Utilization in Obesity (PHASE4)
- Insulin Dextrose Infusion vs Nebulized Salbutamol vs Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Aspart 30 CI brief — competitive landscape report
- Insulin Aspart 30 updates RSS · CI watch RSS
- Medical University of Graz portfolio CI